KalVista Pharmaceuticals, Inc.: 5%+ holders

As of November 10, 2026, KalVista Pharmaceuticals, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 16 filings are on record since August 20, 2025 (Schedule 13G/A, August 14, 2026).

SilverArc Capital Management, LLC also filed stake reports on 8 other companies ↓

Sell to companies like KalVista Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: SilverArc Capital Management, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Tang Capital Management, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-08-11 · Holder: SilverArc Capital Management, LLC · Percent: 0% · SCHEDULE 13G
• Filing 2026-06-10 · Reporting person: Glazer Capital, LLC · Sole voting: 0 · Shared voting: 2,581,700 · Sole dispositive: 0 · Shared dispositive: 2,581,700 · SCHEDULE 13G, 2026-06-10

KalVista Pharmaceuticals, Inc. has 16 Schedule 13D or 13G filings on record since 2025-08-20. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind KalVista Pharmaceuticals, Inc. and the warning signs.

See KalVista Pharmaceuticals, Inc.'s free Snapshot Watch KalVista Pharmaceuticals, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on KalVista Pharmaceuticals, Inc. and the records around it.

Companies that share a holder

• SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
• Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
• Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)

Want the whole picture on KalVista Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on KalVista Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on KalVista Pharmaceuticals, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   17 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies KalVista Pharmaceuticals, Inc. by CUSIP 483497AA1 and gives its principal executive office as 200 Crossing Boulevard, Framingham, MA 01702 (SCHEDULE 13G/A, 2026-08-14).

Timeline

Swipe the table sideways to see every column.

Also on the record for KalVista Pharmaceuticals, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for KalVista Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when KalVista Pharmaceuticals, Inc. is mentioned again
• Find former KalVista Pharmaceuticals, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes